1 / 51

Clinical Considerations in Evidence-based Management of GIST

Clinical Considerations in Evidence-based Management of GIST. Program Goals. GIST Current Treatment Paradigm. What is GIST?. What Causes GIST?. GIST: Treatment. Polling Question #1. Imatinib: Clinical Trial Results. Imatinib: Early Stage GIST. Resistance to Imatinib. Sunitinib .

denali
Download Presentation

Clinical Considerations in Evidence-based Management of GIST

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Considerations in Evidence-based Management of GIST

  2. Program Goals

  3. GISTCurrent Treatment Paradigm

  4. What is GIST?

  5. What Causes GIST?

  6. GIST: Treatment

  7. Polling Question #1

  8. Imatinib: Clinical Trial Results

  9. Imatinib: Early Stage GIST

  10. Resistance to Imatinib

  11. Sunitinib

  12. Regorafenib

  13. Wild-type GIST

  14. GIST Therapy: What Next?

  15. Drug Interactions: Comparison

  16. GISTAdverse Effects and Management Strategies

  17. GIST: Optimizing Patient Outcomes

  18. Polling Question #2

  19. Hypertension

  20. Hypertension (cont)

  21. Other Cardiovascular Risks

  22. Hand Foot Skin Reaction (HFSR)

  23. Hand Foot Skin Reaction (HFSR) (cont)

  24. Other Dermatologic Toxicities

  25. Other Dermatologic Toxicities (cont)

  26. Fatigue

  27. Oral Toxicity

  28. Diarrhea

  29. Nausea

  30. Laboratory Value Abnormalities

  31. Unique to Imatinib

  32. Unique to Regorafenib

  33. Targeted Therapies for GIST: Comparison of Adverse Events (Grades 3 - 4)

  34. GISTEncouraging Adherence to Therapy

  35. Adherence to Therapy

  36. Factors Associated With Non-adherence to Oral Anticancer Therapy

  37. Known Factors Associated With Non-adherence to Oral Anticancer Therapy

  38. Factors Associated With Non-adherence to Oral AnticancerTherapy (cont)

  39. Polling Question #3

  40. Adherence With TKIs

  41. Adherence With TKIs (cont)

  42. Consider Over-adherence

  43. Role of Nurse and Clinical Pharmacist

  44. Role of Nurse and Clinical Pharmacist (cont)

  45. Abbreviations

  46. Abbreviations (cont)

  47. References

  48. References (cont)

  49. References (cont)

More Related